Administration of the engineered exosome delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which could selectively silence STAT6 expression in TAMs, induces reprogramming of TAMs and remodeling of the tumor microenvironment [171]. Here, STAT6 is linked to neoplasm.